OPEN ENROLLMENT
Mercury Study
A Phase 3 Prospective, Randomized, Multi-Center, Open-Label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy with MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants.
Funded by: Medeor Therapeutics, Inc.
Dear Patient,
I am writing to let you know about an opportunity to participate in a research study designed for patients with Living Kidney Donor Transplant. This study is being conducted by myself, Dr. Piotr Witkowski at the University of Chicago.
The purpose of this study is to determine is a single infusion of MDR-101 can prevent the immune system from rejecting a transplanted kidney without any or minimal anti-rejection drugs.
You may be eligible for this study if:
-
you are between the ages of 18-65,
-
are in need of a single solid organ (kidney transplant).
-
Plan on being a recipient of a first kidney allograft from an HLA-matched, living related donor? HLA-matched defined as identical for both alleles at the following genetic loci: HLA-A, HLA-B, and HLA-DRB1.
If you are interested in learning more about this study, please review "Brief description" and "the patient information sheet" and contact Lindsay Basto, RN, BSN, Lindsay.Basto@uchicago.edu or 773-702-2504, for more information.
It is important to know that this letter is not to tell you to join the study.
It is your decision, and your participation is voluntary.
Whether you show interest, and participate in the study or not, it will have no effect on your treatment with your doctors.
Thank you for your interest and consideration,
Piotr Witkowski M.D. Ph.D